Aurobindo Pharma Limited (AUROPHARMA.BO)
INR 1096.8
(0.16%)
INR 1096.8
(0.16%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 42.2 Billion INR | 67.79% |
| 2022 | 25.75 Billion INR | -22.65% |
| 2021 | 33.29 Billion INR | -23.78% |
| 2020 | 43.68 Billion INR | 11.99% |
| 2019 | 39 Billion INR | 28.82% |
| 2018 | 30.28 Billion INR | 0.17% |
| 2017 | 30.22 Billion INR | 7.81% |
| 2016 | 28.03 Billion INR | 8.58% |
| 2015 | 25.82 Billion INR | 11.7% |
| 2014 | 23.11 Billion INR | 37.47% |
| 2013 | 16.81 Billion INR | 214.42% |
| 2012 | 5.34 Billion INR | 149.5% |
| 2011 | 2.14 Billion INR | -75.5% |
| 2010 | 8.74 Billion INR | 6.68% |
| 2009 | 8.2 Billion INR | 424.06% |
| 2008 | 1.56 Billion INR | -56.72% |
| 2007 | 3.61 Billion INR | 23.48% |
| 2006 | 2.92 Billion INR | 112.17% |
| 2005 | 1.37 Billion INR | 102.3% |
| 2004 | 682.1 Million INR | -65.49% |
| 2003 | 1.97 Billion INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 12.15 Billion INR | -8.81% |
| 2023 Q3 | 11.78 Billion INR | 19.51% |
| 2023 Q1 | 8.24 Billion INR | 25.62% |
| 2023 Q2 | 9.85 Billion INR | 19.51% |
| 2023 FY | 43.21 Billion INR | 67.79% |
| 2023 Q4 | 13.32 Billion INR | 13.13% |
| 2022 Q3 | 6.33 Billion INR | 17.49% |
| 2022 Q2 | 5.38 Billion INR | -21.37% |
| 2022 Q1 | 6.85 Billion INR | -4.94% |
| 2022 FY | 25.75 Billion INR | -22.65% |
| 2022 Q4 | 6.56 Billion INR | 3.73% |
| 2021 Q1 | 9.29 Billion INR | -7.83% |
| 2021 Q4 | 7.2 Billion INR | 0.5% |
| 2021 Q3 | 7.17 Billion INR | -19.64% |
| 2021 FY | 33.29 Billion INR | -23.78% |
| 2021 Q2 | 8.92 Billion INR | -4.0% |
| 2020 FY | 43.68 Billion INR | 11.99% |
| 2020 Q3 | 12.11 Billion INR | 0.19% |
| 2020 Q2 | 12.08 Billion INR | 9.34% |
| 2020 Q1 | 11.05 Billion INR | -1.56% |
| 2020 Q4 | 10.08 Billion INR | -16.71% |
| 2019 Q2 | 9.17 Billion INR | -0.91% |
| 2019 Q4 | 11.22 Billion INR | 13.64% |
| 2019 FY | 39 Billion INR | 28.82% |
| 2019 Q1 | 9.26 Billion INR | 1.18% |
| 2019 Q3 | 9.88 Billion INR | 7.69% |
| 2018 Q2 | 8.49 Billion INR | 41.36% |
| 2018 Q4 | 9.15 Billion INR | -7.52% |
| 2018 FY | 30.28 Billion INR | 0.17% |
| 2018 Q1 | 6 Billion INR | -11.13% |
| 2018 Q3 | 9.89 Billion INR | 16.56% |
| 2017 Q3 | 9.2 Billion INR | -7.58% |
| 2017 FY | 30.22 Billion INR | 7.81% |
| 2017 Q4 | 6.75 Billion INR | -26.59% |
| 2017 Q2 | 9.96 Billion INR | 37.18% |
| 2017 Q1 | 7.26 Billion INR | 9.42% |
| 2016 Q4 | 6.63 Billion INR | -18.11% |
| 2016 Q1 | 8.06 Billion INR | 2.6% |
| 2016 FY | 28.03 Billion INR | 8.58% |
| 2016 Q2 | 8.47 Billion INR | 5.05% |
| 2016 Q3 | 8.1 Billion INR | -4.33% |
| 2015 FY | 25.82 Billion INR | 11.7% |
| 2015 Q4 | 7.85 Billion INR | 6.22% |
| 2015 Q3 | 7.39 Billion INR | 13.02% |
| 2015 Q2 | 6.54 Billion INR | -0.03% |
| 2015 Q1 | 6.54 Billion INR | 2.48% |
| 2014 Q3 | 5.6 Billion INR | 5.26% |
| 2014 Q4 | 6.39 Billion INR | 13.98% |
| 2014 FY | 23.11 Billion INR | 37.47% |
| 2014 Q1 | 5.79 Billion INR | -21.93% |
| 2014 Q2 | 5.32 Billion INR | -8.1% |
| 2013 Q3 | 5.73 Billion INR | 92.09% |
| 2013 FY | 16.81 Billion INR | 214.42% |
| 2013 Q2 | 2.98 Billion INR | 343.61% |
| 2013 Q1 | 673 Million INR | -68.39% |
| 2013 Q4 | 7.42 Billion INR | 29.45% |
| 2012 Q3 | 1.3 Billion INR | -58.51% |
| 2012 Q2 | 3.14 Billion INR | 355.2% |
| 2012 Q4 | 2.12 Billion INR | 63.03% |
| 2012 FY | 5.34 Billion INR | 149.5% |
| 2012 Q1 | -1.23 Billion INR | -162.89% |
| 2011 Q3 | -33.2 Million INR | 0.0% |
| 2011 FY | 2.14 Billion INR | -75.5% |
| 2011 Q4 | 1.96 Billion INR | 6006.33% |
| 2010 FY | 8.74 Billion INR | 6.68% |
| 2009 FY | 8.2 Billion INR | 424.06% |
| 2008 FY | 1.56 Billion INR | -56.72% |
| 2007 FY | 3.61 Billion INR | 23.48% |
| 2006 FY | 2.92 Billion INR | 112.17% |
| 2005 FY | 1.37 Billion INR | 102.3% |
| 2004 FY | 682.1 Million INR | -65.49% |
| 2003 FY | 1.97 Billion INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | -632.933% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | -370.009% |
| Granules India Limited | 6.81 Billion INR | -519.111% |
| Indoco Remedies Limited | 1.29 Billion INR | -3165.099% |
| Achyut Healthcare Limited | 4.43 Million INR | -950846.372% |
| Ajanta Pharma Limited | 19.67 Billion INR | -114.476% |
| Alkem Laboratories Limited | 19.46 Billion INR | -116.849% |
| Alpa Laboratories Limited | 184.49 Million INR | -22774.627% |
| Brooks Laboratories Limited | 14.44 Million INR | -292164.543% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | -2357.234% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -3328.348% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 37.688% |
| Eris Lifesciences Limited | 5.18 Billion INR | -714.459% |
| FDC Limited | 2.98 Billion INR | -1313.263% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | -549.039% |
| Gufic Biosciences Limited | 1.32 Billion INR | -3073.373% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | -854.7% |
| Ipca Laboratories Limited | 7.98 Billion INR | -428.82% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -8205.552% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 27872.988% |
| Lasa Supergenerics Limited | -458 Million INR | 9314.528% |
| Laurus Labs Limited | 3.94 Billion INR | -968.809% |
| Lupin Limited | 28.04 Billion INR | -50.486% |
| Mankind Pharma Limited | 21.51 Billion INR | -96.128% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -41976.77% |
| Megasoft Limited | -121.1 Million INR | 34948.56% |
| NATCO Pharma Limited | 25.96 Billion INR | -62.557% |
| Piramal Pharma Limited | 4.55 Billion INR | -826.134% |
| RPG Life Sciences Limited | 2.29 Billion INR | -1741.077% |
| Sigachi Industries Limited | 1.47 Billion INR | -2763.363% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 59.538% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | -815.935% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -16831.928% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | -7307.726% |
| Windlas Biotech Limited | 1.29 Billion INR | -3149.159% |
| ZIM Laboratories Limited | 253.82 Million INR | -16526.548% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 2.097% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 1125.579% |
| Divi's Laboratories Limited | 33.08 Billion INR | -27.579% |
| Hester Biosciences Limited | 364.81 Million INR | -11468.488% |
| Procter & Gamble Health Limited | 2.78 Billion INR | -1414.824% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -9123.812% |
| Bal Pharma Limited | 233.9 Million INR | -17942.487% |
| Strides Pharma Science Limited | 5.22 Billion INR | -707.588% |
| Venus Remedies Limited | 534.65 Million INR | -7793.56% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | -1249.151% |
| Nectar Lifesciences Limited | 923.8 Million INR | -4468.383% |
| Shilpa Medicare Limited | 1.36 Billion INR | -2988.916% |
| Aarti Drugs Limited | 7.14 Billion INR | -490.357% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | -2542.973% |
| Suven Life Sciences Limited | -1.22 Billion INR | 3542.833% |
| Ind-Swift Limited | 1.22 Billion INR | -3342.434% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | -195.481% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 1195.357% |
| Themis Medicare Limited | 392.58 Million INR | -10649.919% |
| Hikal Limited | 32.11 Million INR | -131332.576% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | -66.579% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | -6636.313% |
| Wockhardt Limited | -670 Million INR | 6398.955% |
| Jubilant Pharmova Limited | 5.18 Billion INR | -713.317% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -465269.899% |
| Neuland Laboratories Limited | 5.31 Billion INR | -693.574% |
| Morepen Laboratories Limited | 4.17 Billion INR | -911.133% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -20185.028% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -153600.197% |